Xi Liu

15.9k total citations · 1 hit paper
67 papers, 1.8k citations indexed

About

Xi Liu is a scholar working on Cancer Research, Molecular Biology and Cell Biology. According to data from OpenAlex, Xi Liu has authored 67 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Cancer Research, 39 papers in Molecular Biology and 16 papers in Cell Biology. Recurrent topics in Xi Liu's work include Cancer-related molecular mechanisms research (16 papers), MicroRNA in disease regulation (13 papers) and Microtubule and mitosis dynamics (11 papers). Xi Liu is often cited by papers focused on Cancer-related molecular mechanisms research (16 papers), MicroRNA in disease regulation (13 papers) and Microtubule and mitosis dynamics (11 papers). Xi Liu collaborates with scholars based in China, United States and Denmark. Xi Liu's co-authors include Ethan Dmitrovsky, Sarah J. Freemantle, Lorenzo F. Sempere, Murray Korc, Sakari Kauppinen, James DiRenzo, Mads Bak, Konstantin H. Dragnev, Vincent A. Memoli and Qingyu Zhang and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Xi Liu

60 papers receiving 1.7k citations

Hit Papers

Current status of sorafenib nanoparticle delivery systems... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma
    2021 151 citations Fanhua Kong, Qifa Ye et al. Theranostics profile →

Peers

Xi Liu
Shujuan Shao China
Xian Lin China
Vivi Kasim China
Xiaohu Tang United States
Jagadish C. Ghosh United States
Guopei Zheng China
Shujuan Shao China
Xi Liu
Citations per year, relative to Xi Liu Xi Liu (= 1×) peers Shujuan Shao

Countries citing papers authored by Xi Liu

Since Specialization
Citations

This map shows the geographic impact of Xi Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xi Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xi Liu more than expected).

Fields of papers citing papers by Xi Liu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xi Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xi Liu. The network helps show where Xi Liu may publish in the future.

Co-authorship network of co-authors of Xi Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Xi Liu. A scholar is included among the top collaborators of Xi Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xi Liu. Xi Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Liu, Xi, et al.. (2025). Unraveling LncRNA GAS5 in Atherosclerosis: Mechanistic Insights and Clinical Translation. Biology. 14(6). 697–697. 1 indexed citations
2.
Jin, Haoyi, Yunchao Zhang, Chang-Qi Li, et al.. (2025). Mannose inhibits PKM2 lactylation to induce pyroptosis in bladder cancer and activate antitumor immune responses. Communications Biology. 8(1). 689–689. 4 indexed citations
3.
Li, Zeyu, Fei Du, Nanbin Liu, et al.. (2025). Macrophage DHX34 as a negative regulator of the CX3CL1–CX3CR1 axis and CD8+ T-cell infiltration in hepatocellular carcinoma. International Immunopharmacology. 169. 116014–116014.
4.
Li, Bo, Ping Zhang, Junlin Li, et al.. (2024). Allogeneic “Zombie Cell” as Off‐The‐Shelf Vaccine for Postsurgical Cancer Immunotherapy. Advanced Science. 11(13). e2307030–e2307030. 6 indexed citations
5.
Liu, Xi, Simin Wen, Kaixiang Zhang, et al.. (2023). Comparative miRNA-seq analysis revealed molecular mechanisms of red color formation in the early developmental stages of Plectropomus leopardus. Frontiers in Marine Science. 10. 4 indexed citations
6.
Jin, Haoyi, Xi Liu, & Hongxu Liu. (2023). Biological function, regulatory mechanism, and clinical application of mannose in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1878(6). 188970–188970. 18 indexed citations
7.
Liu, Xi, Jun Quan, Zhijian Chen, et al.. (2022). Metallothionein 2A (MT2A) controls cell proliferation and liver metastasis by controlling the MST1/LATS2/YAP1 signaling pathway in colorectal cancer. Cancer Cell International. 22(1). 205–205. 21 indexed citations
8.
Liu, Xi, Shuangjie Liu, Chiyuan Piao, et al.. (2021). Non‐metabolic function of MTHFD2 activates CDK2 in bladder cancer. Cancer Science. 112(12). 4909–4919. 23 indexed citations
9.
Kong, Fanhua, Qifa Ye, Xiongying Miao, et al.. (2021). Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 11(11). 5464–5490. 151 indexed citations breakdown →
10.
Kawakami, Masanori, Lisa Maria Mustachio, Yulong Chen, et al.. (2020). A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Molecular Cancer Therapeutics. 20(3). 477–489. 13 indexed citations
11.
Liu, Xi, Yun Lu, Zibo Chen, et al.. (2020). The Ubiquitin-Specific Peptidase USP18 Promotes Lipolysis, Fatty Acid Oxidation, and Lung Cancer Growth. Molecular Cancer Research. 19(4). 667–677. 35 indexed citations
12.
Liu, Yuanxing, Xi Liu, Arndt F. Schilling, et al.. (2020). MicroRNA-191 regulates differentiation and migration of mesenchymal stem cells and their paracrine effect on angiogenesis. Biotechnology Letters. 42(9). 1777–1788. 7 indexed citations
13.
Yaung, Stephanie J., et al.. (2020). Assessment of a Highly Curated Somatic Oncology Database to Aid in the Interpretation of Clinically Important Variants in Next-Generation Sequencing Results. Journal of Molecular Diagnostics. 22(11). 1356–1366. 3 indexed citations
14.
Zhang, Xiaotong, Xi Liu, Jianbin Bi, et al.. (2019). The circINTS4/miR-146b/CARMA3 axis promotes tumorigenesis in bladder cancer. Cancer Gene Therapy. 27(3-4). 189–202. 23 indexed citations
15.
Danilov, Alexey V., Shanhu Hu, Bernardo Orr, et al.. (2016). Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2. Molecular Cancer Therapeutics. 15(11). 2758–2766. 36 indexed citations
16.
Du, Xiaoli, Xiaolan Qian, Alex G. Papageorge, et al.. (2012). Functional Interaction of Tumor Suppressor DLC1 and Caveolin-1 in Cancer Cells. Cancer Research. 72(17). 4405–4416. 42 indexed citations
17.
Blanchard, Véronique, Xi Liu, Matthias Kaup, et al.. (2011). N‐glycosylation and biological activity of recombinant human alpha1‐antitrypsin expressed in a novel human neuronal cell line. Biotechnology and Bioengineering. 108(9). 2118–2128. 49 indexed citations
18.
Liu, Xi, Lorenzo F. Sempere, Yongli Guo, et al.. (2011). Involvement of microRNAs in lung cancer biology and therapy. Translational research. 157(4). 200–208. 27 indexed citations
19.
Liu, Xi, Lorenzo F. Sempere, Fabrizio Galimberti, et al.. (2009). Uncovering Growth-Suppressive MicroRNAs in Lung Cancer. Clinical Cancer Research. 15(4). 1177–1183. 151 indexed citations
20.
Sempere, Lorenzo F., Xi Liu, & Ethan Dmitrovsky. (2009). Tumor-Suppressive microRNAs in Lung Cancer: Diagnostic and Therapeutic Opportunities. The Scientific World JOURNAL. 9. 626–628. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shujuan Shao Breakdown of academic impact, for papers by Xian Lin Breakdown of academic impact, for papers by Vivi Kasim Breakdown of academic impact, for papers by Xiaohu Tang Breakdown of academic impact, for papers by Jagadish C. Ghosh Breakdown of academic impact, for papers by Guopei Zheng
Rankless by CCL
2026